Access count of this item: 297

Files in This Item:
File Description SizeFormat 
44_627.pdf329.77 kBAdobe PDFView/Open
Title: 表在性膀胱癌に対するBCG膀胱内注入療法の再発予防効果
Other Titles: Intravesical BCG therapy for superficial bladder cancer
Authors: 瀬川, 直樹  KAKEN_name
岩本, 勇作  KAKEN_name
東, 治人  KAKEN_name
山本, 員久  KAKEN_name
上田, 陽彦  KAKEN_name
勝岡, 洋治  KAKEN_name
Author's alias: SEGAWA, Naoki
IWAMOTO, Yusaku
AZUMA, Haruhito
YAMAMOTO, Kazuhisa
UEDA, Haruhiko
KATSUOKA, Yoji
Keywords: Bladder cancer
Intravesical instillation of BCG
Issue Date: Sep-1998
Publisher: 泌尿器科紀要刊行会
Journal title: 泌尿器科紀要
Volume: 44
Issue: 9
Start page: 627
End page: 631
Abstract: 表在性膀胱癌35例に対しBCG膀胱内注入療法を施行した.BCG膀注は既往の抗癌剤膀注療法に抵抗した症例にも有効であり,再発延長効果のある可能性が考えられた.BCG膀注後再発例においても2コースで優れた再発予効果を示し,病期進展を抑制する可能性があることが示唆された
Intravesical instillation of Tokyo 172 strain bacillus Calmette-Guerin (BCG) after transurethral resection of bladder tumor (TUR-Bt) was applied to 35 patients with superficial bladder cancer. The patients received 80 mg of BCG in 40 ml saline infused into the bladder once a week for 6 weeks. Actuarial non-recurrence rates for all 35 patients were 81.7% and 58.4% at one and two years after the BCG therapy, respectively. The recurrence of the bladder cancer after the BCG therapy was observed in 12 patients 3-27 months later. Seven patients received an additional course of BCG instillation, and 6 (86%) showed no further recurrence. Thus, the overall success rate of 2 cycles of BCG instillation was 83% (29 of 35 patients). Moreover, in some cases intravesical BCG instillation was effective for recurrent superficial bladder cancer after intravesical instillation of anti-cancer agents and prolonged the period until recurrence. The progression rate was only 5% (2 of 35 patients). These results suggest that intravesical BCG therapy for superficial bladder cancer helps prevent disease progression.
URI: http://hdl.handle.net/2433/116258
PubMed ID: 9805666
Appears in Collections:Vol.44 No.9

Show full item record

Export to RefWorks


Export Format: 


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.